<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Fine-Tuning ChemBERTa for Predicting Inhibitory Activity Against TDP1 Using Deep Learning - Health AI Hub</title>
    <meta name="description" content="This paper introduces a deep learning framework utilizing fine-tuned ChemBERTa models to accurately predict the pIC50 values of small molecules against Tyrosyl-">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Fine-Tuning ChemBERTa for Predicting Inhibitory Activity Against TDP1 Using Deep Learning</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2512.04252v1" target="_blank">2512.04252v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-12-03
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Baichuan Zeng
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG, cs.AI
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.95 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2512.04252v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2512.04252v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces a deep learning framework utilizing fine-tuned ChemBERTa models to accurately predict the pIC50 values of small molecules against Tyrosyl-DNA Phosphodiesterase 1 (TDP1) directly from their SMILES strings. Addressing the challenge of cancer chemoresistance, the approach leverages a large, imbalanced dataset and systematically evaluates pre-training strategies, outperforming classical baselines and demonstrating competitive virtual screening utility. The resulting model offers a robust, 3D-structure-free tool to accelerate the discovery of TDP1 inhibitors.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>TDP1 is a key target in overcoming cancer chemoresistance, meaning its inhibition can make existing cancer treatments more effective. This work provides a computational method to efficiently identify and prioritize potential TDP1 inhibitors, which is critical for developing new strategies against drug-resistant cancers.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The AI application involves using deep learning models (fine-tuned ChemBERTa) to predict the inhibitory potency (pIC50 values) of small molecules against a specific biological target, TDP1, directly from their SMILES strings. This AI-driven prediction capability serves as a 'ready-to-deploy tool for prioritizing TDP1 inhibitors for experimental testing,' thereby accelerating target-specific drug discovery for overcoming cancer chemoresistance. It automates and optimizes a crucial step in the drug development pipeline for a specific medical condition.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>**Problem Addressed**: Predicts inhibitory potency against TDP1, a crucial target for overcoming cancer chemoresistance, which is a significant challenge in early drug discovery.</li>
                    
                    <li>**Methodology**: Develops a deep learning framework using fine-tuned variants of ChemBERTa, a pre-trained chemical language model, for quantitative regression of pIC50 values from molecular SMILES strings.</li>
                    
                    <li>**Data Handling**: Utilizes a large-scale consensus dataset of 177,092 compounds, addressing severe activity imbalance (only 2.1% active) through stratified data splits and sample weighting.</li>
                    
                    <li>**Pre-training Strategies**: Evaluates two pre-training strategies: Masked Language Modeling (MLM) and Masked Token Regression (MTR) for optimizing model performance.</li>
                    
                    <li>**Performance Metrics**: Achieves significant performance over Random Predictor baselines in regression accuracy and virtual screening utility, demonstrating competitive results compared to Random Forest.</li>
                    
                    <li>**Virtual Screening Utility**: Exhibits high enrichment factor (EF@1% 17.4) and precision (Precision@1% 37.4) among the top 1% of ranked predictions, indicating strong capability in identifying active compounds.</li>
                    
                    <li>**Validation & Deployability**: Validated through rigorous ablation and hyperparameter studies, yielding a robust, ready-to-deploy tool for prioritizing TDP1 inhibitors for experimental testing without needing 3D structural information.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The study employs a deep learning framework based on fine-tuning ChemBERta, a pre-trained chemical language model, for quantitative regression of pIC50 values. Molecular SMILES strings serve as input. Two pre-training strategies, Masked Language Modeling (MLM) and Masked Token Regression (MTR), were systematically evaluated. A large consensus dataset of 177,092 compounds was used, with stratified data splits and sample weighting implemented to counteract severe activity imbalance. Model robustness was ensured through rigorous ablation and hyperparameter studies.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The fine-tuned ChemBERTa models significantly outperformed classical Random Predictor baselines in both regression accuracy and virtual screening utility. The approach demonstrated competitive performance against Random Forest, achieving an impressive enrichment factor (EF@1%) of 17.4 and precision (Precision@1%) of 37.4 for top-ranked predictions. The model provides accurate, 3D-structure-free pIC50 predictions directly from SMILES.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This research provides a highly efficient and accurate computational tool for early-stage drug discovery, specifically for identifying TDP1 inhibitors. By streamlining the prioritization of promising small molecules, it can significantly reduce the time, cost, and experimental burden associated with developing new therapeutic agents to combat cancer chemoresistance, ultimately leading to faster development of more effective cancer treatments.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly state any limitations of the study.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The abstract does not explicitly mention specific future research directions, though it broadly highlights the "transformative potential of chemical transformers in accelerating target-specific drug discovery".</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Pharmacology</span>
                    
                    <span class="tag">Drug Development</span>
                    
                    <span class="tag">Medicinal Chemistry</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">TDP1</span>
                    
                    <span class="tag tag-keyword">ChemBERTa</span>
                    
                    <span class="tag tag-keyword">Deep Learning</span>
                    
                    <span class="tag tag-keyword">Drug Discovery</span>
                    
                    <span class="tag tag-keyword">Cancer Chemoresistance</span>
                    
                    <span class="tag tag-keyword">pIC50 prediction</span>
                    
                    <span class="tag tag-keyword">SMILES</span>
                    
                    <span class="tag tag-keyword">Chemical Transformers</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Predicting the inhibitory potency of small molecules against Tyrosyl-DNA Phosphodiesterase 1 (TDP1)-a key target in overcoming cancer chemoresistance-remains a critical challenge in early drug discovery. We present a deep learning framework for the quantitative regression of pIC50 values from molecular Simplified Molecular Input Line Entry System (SMILES) strings using fine-tuned variants of ChemBERTa, a pre-trained chemical language model. Leveraging a large-scale consensus dataset of 177,092 compounds, we systematically evaluate two pre-training strategies-Masked Language Modeling (MLM) and Masked Token Regression (MTR)-under stratified data splits and sample weighting to address severe activity imbalance which only 2.1% are active. Our approach outperforms classical baselines Random Predictor in both regression accuracy and virtual screening utility, and has competitive performance compared to Random Forest, achieving high enrichment factor EF@1% 17.4 and precision Precision@1% 37.4 among top-ranked predictions. The resulting model, validated through rigorous ablation and hyperparameter studies, provides a robust, ready-to-deploy tool for prioritizing TDP1 inhibitors for experimental testing. By enabling accurate, 3D-structure-free pIC50 prediction directly from SMILES, this work demonstrates the transformative potential of chemical transformers in accelerating target-specific drug discovery.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>